Multivariable analysis of mutant NPM1 MRD in patients with AML with a FLT3-ITD at diagnosis
| Prognostic factor . | Relapse incidence . | |
|---|---|---|
| HR (95% CI) . | P value . | |
| Mutant NPM1 MRD status (detectable vs not detectable) | 4.79 (1.84-12.44) | .001 |
| Age (per year) | 1.00 (0.97-1.04) | .86 |
| No. of cycles to attain CR (2 vs 1 cycle) | 0.70 (0.26-1.85) | .47 |
| WBC counts at diagnosis (>100 × 109 vs ≤100 × 109) | 1.59 (0.78-3.22) | .20 |
| Prognostic factor . | Relapse incidence . | |
|---|---|---|
| HR (95% CI) . | P value . | |
| Mutant NPM1 MRD status (detectable vs not detectable) | 4.79 (1.84-12.44) | .001 |
| Age (per year) | 1.00 (0.97-1.04) | .86 |
| No. of cycles to attain CR (2 vs 1 cycle) | 0.70 (0.26-1.85) | .47 |
| WBC counts at diagnosis (>100 × 109 vs ≤100 × 109) | 1.59 (0.78-3.22) | .20 |
WBC, white blood cell.